-+ 0.00%
-+ 0.00%
-+ 0.00%

Contineum launches global Phase 2 trial of PIPE-791 in idiopathic pulmonary fibrosis patients

PUBT·06/30/2026 20:06:07
Listen to the news
Contineum launches global Phase 2 trial of PIPE-791 in idiopathic pulmonary fibrosis patients
  • Contineum Therapeutics highlighted PIPE-791, an oral LPAR1 antagonist now in a global Phase 2 trial in idiopathic pulmonary fibrosis.
  • No clinical results were presented; the update centered on a newly published discovery paper dated June 29, 2026.
  • Preclinical findings described sustained receptor coverage with once-daily dosing, supporting plans to pursue fibrotic disease and pain indications.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Contineum Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606301605BIZWIRE_USPR_____20260630_BW868477) on June 30, 2026, and is solely responsible for the information contained therein.